The intersection of health and technology holds unparalleled potential to improve lives. We invest in the innovators who drive advancements in preventing, identifying and curing disease.
We invest across the Health & Life Sciences value chain, focusing on enabling technologies, platforms and software that drive sector-wide innovation, delivering substantial benefits to healthcare providers, patients and payers.
Data science and technology is transforming healthcare delivery and drug development. We back founders and teams that are harnessing innovation to solve critical healthcare challenges. Areas we are particularly interested in:
Precision Medicine & Diagnostics
From AI-powered analysis to novel biomarker platforms, we support technologies that enable earlier detection and more targeted treatments.
Digital Biology & Drug Development
We invest in computational platforms and tools that accelerate therapeutic discovery, optimise clinical trials and enhance manufacturing processes.
Healthcare Intelligence
Transformative software solutions that improve clinical decision-making, streamline regulatory compliance and enhance operational efficiency.
Regenerative Medicine & Advanced Therapeutics
We back platform technologies that enable next-generation treatments, from tissue engineering to targeted drug delivery systems.
Portfolio spotlight: Wobble Genomics
Wobble Genomics
RNA and DNA sequencing specialists
In March of this year, Mercia Ventures led a £8.5million fundraise into Edinburgh-based Wobble Genomics Ltd.
Wobble has found a way to detect previously invisible ‘full length’ RNA, and the technology could have wide-ranging applications, from drug development and research to agriculture and ecology.
To find out a bit more, Mercia TV travelled to Scotland to speak to CEO and Founder Dr Richard Kuo.
Together, we can transform scientific breakthroughs into real-world healthcare solutions.